Unusual clinical case: Pharmabortion in a patient with a donor kidney

The study presents an algorithm for drug-induced abortion and prevention of complications after the procedure, with a clinical efficacy rate of 99.7%. In addition, a unique case is presented, involving the use of drugs to terminate a short-term pregnancy in a patient with chronic glomerulonephritis that affecting her kidney and chronic pyelonephritis in a previously transplanted second kidney. Given the lack of urinary organ dysfunction and the absence of clinical worsening of any somatic pathology at present, the medical consilium has determined that pharmabortion is permissible under dynamic monitoring of the patient. A single oral dose of 600 mg of mifepristone, followed by twice-daily administration of 400 mcg of misoprostol (per os) 36 h later, effectively terminated the unwanted pregnancy without adverse effects on extragenital diseases. Administering the gestagenic drug during the second phase of the menstrual cycle after abortion prevented ovarian dysfunction and endometrial hyperplasia.